TY - CHAP M1 - Book, Section TI - Evaluation of Patients with Known Coronary Artery Disease A1 - Gomez, Javier A1 - Doukky, Rami A2 - Heller, Gary V. A2 - Hendel, Robert C. PY - 2022 T2 - Nuclear Cardiology: Practical Applications, 4e AB - KEY POINTSIn patients with known coronary artery disease (CAD), abnormal single-photon emission computed tomography (SPECT) or positron emission tomography (PET) myocardial perfusion imaging (MPI) is associated with an increase in risk of adverse cardiac events, proportional to the extent and severity of the perfusion abnormalities.SPECT and PET MPI can determine extent, severity, and localization of perfusion abnormalities in patients with multivessel CAD or prior revascularization procedures, guiding management strategies.Routine MPI testing after coronary revascularization in patients with stable or no symptoms is not supported by current guidelines.SPECT and PET MPI provide safe and effective risk stratification in patients presenting with acute coronary syndromes or myocardial infarction who have not received or have a contraindication to invasive coronary angiography.SPECT and PET MPI can be useful to assess response to medical therapy in patients with established CAD. SN - PB - McGraw Hill LLC CY - New York, NY Y2 - 2024/03/28 UR - accesscardiology.mhmedical.com/content.aspx?aid=1190157123 ER -